LAVA

Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery…

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific…

<!-- Name:DistributionId Value:8782636 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8745455 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma…

NOVI SAD, Serbia, Jan. 4, 2023 /PRNewswire/ -- RT-RK, a leading embedded software development house, announces the launch of its latest product - LAVA, a revolutionary software tool for enabling access to ADAS functions from Android…

UTRECHT, The Netherlands and PHILADELPHIA, Pa., Dec. 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific…